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Objectives:	 Mesenchymal	 stromal	 cells	 are	 being	 investigated	
as	a	cell-based	therapy	for	a	number	of	disease	processes,	with	
promising	results	in	animal	models	of	systemic	inflammation	and	
sepsis.	Studies	are	ongoing	to	determine	ways	to	further	improve	
the	 therapeutic	 potential	 of	 mesenchymal	 stromal	 cells.	 A	 gas	
molecule	that	improves	outcome	in	experimental	sepsis	is	carbon	
monoxide.	We	hypothesized	that	preconditioning	of	mesenchymal	
stromal	cells	with	carbon	monoxide	ex	vivo	would	promote	further	
therapeutic	benefit	when	cells	are	administered	 in	vivo	after	 the	
onset	of	polymicrobial	sepsis	in	mice.
Design:	Animal	study	and	primary	cell	culture.
Setting:	Laboratory	investigation.
Subjects:	BALB/c	mice.
Interventions:	 Polymicrobial	 sepsis	 was	 induced	 by	 cecal	 liga-
tion	 and	 puncture.	 Mesenchymal	 stromal	 cells,	 mesenchymal	
stromal	 cells-conditioned	 with	 carbon	 monoxide,	 fibroblasts,	 or	
fibroblasts-conditioned	with	carbon	monoxide	were	delivered	by	
tail	 vein	 injections	 to	 septic	mice.	 The	mice	were	 assessed	 for	
survival,	bacterial	clearance,	and	the	inflammatory	response	dur-
ing	sepsis	in	each	of	the	groups.	Mesenchymal	stromal	cells	were	
also	assessed	for	their	ability	to	promote	bacterial	phagocytosis	
by	 neutrophils,	 the	 production	 of	 specialized	 proresolving	 lipid	
mediators,	 and	 their	 importance	 for	mesenchymal	 stromal	 cells	
function	using	gene	silencing.
Measurements and Main Results:	Ex	vivo	preconditioning	with	car-
bon	monoxide	allowed	mesenchymal	stromal	cells	to	be	adminis-
tered	 later	after	 the	onset	of	sepsis	(6	hr),	and	yet	maintain	 their	
therapeutic	effect	with	 increased	survival.	Carbon	monoxide	pre-
conditioned	mesenchymal	stromal	cells	were	also	able	to	alleviate	
organ	injury,	improve	bacterial	clearance,	and	promote	the	resolu-
tion	of	inflammation.	Mesenchymal	stromal	cells	exposed	to	carbon	
monoxide,	with	docosahexaenoic	 acid	 substrate,	 produced	 spe-
cialized	proresolving	lipid	mediators,	particularly	D-series	resolvins,	
which	 promoted	 survival.	 Silencing	 of	 lipoxygenase	 pathways	
(5-lipoxygenase	 and	 12/15-lipoxygenase),	 which	 are	 important	
enzymes	for	specialized	proresolving	 lipid	mediator	biosynthesis,	
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resulted	in	a	loss	of	therapeutic	benefit	bestowed	on	mesenchymal	
stromal	cells	by	carbon	monoxide.
Conclusions:	Taken	together,	these	data	suggest	that	production	
of	specialized	proresolving	lipid	mediators	contribute	to	improved	
mesenchymal	stromal	cell	efficacy	when	exposed	to	carbon	mon-
oxide,	resulting	in	an	improved	therapeutic	response	during	sep-
sis.	(Crit Care Med	2016;	44:e1236–e1245)
Key Words:	mesenchymal	stromal	cells;	neutrophils;	phagocytosis;	
sepsis;	specialized	proresolving	lipid	mediators
Sepsis is a disease process initiated by an underlying severe infection that leads to a systemic inflammatory response (1–4). The desired outcome in sepsis is for the 
invading microorganism(s) to be cleared, followed by resolu-
tion of the inflammatory process (5), allowing homeostasis 
to be achieved and permanent organ dysfunction avoided. 
Although in the past the resolution of inflammation was felt 
to be a passive process, it has been demonstrated that special-
ized proresolving lipid mediators (SPMs) control this process 
in an orchestrated manner, stopping neutrophil influx and 
activating resolution pathways (6). These bioactive mediators 
are synthesized from omega-3 fatty acids (docosahexaenoic 
acid [DHA] and eicosapentaenoic acid). Omega-6 fatty acids 
also contribute to the production of SPMs; however, the ara-
chidonic acid (AA)–derived mediators also include the proin-
flammatory eicosanoids (6).
Even with recent advances in standard of care, severe sepsis 
and septic shock remain associated with high rates of morbid-
ity and mortality (7, 8). Investigators have recently begun to 
explore cell-based therapies for sepsis, including the use of 
mesenchymal stromal cells (MSCs) (9, 10). MSCs are consid-
ered to be a promising platform for cell-based therapy, and in 
preclinical animal models, the administration of MSCs has 
shown improved outcome in polymicrobial sepsis induced by 
cecal ligation and puncture (CLP) in mice (11–15). The benefit 
of treating with MSCs during CLP, or single organism bacterial 
peritonitis, appears to be better when given early (1–4 hr) after 
the onset of sepsis (11–13, 15), whereas later administration 
(6 hr) may require the addition of antibiotics for improved 
survival (14). Thus, timing of MSC administration in regard 
to the onset of sepsis is a very important factor determining 
therapeutic benefit.
Heme oxygenase (HO)-1 is an important cytoprotec-
tive molecule during experimental sepsis in mice (16–19). 
We previously demonstrated the benefits of MSCs when 
administered after the onset of polymicrobial sepsis in mice, 
although these effects were not dependent on endogenous 
HO-1 (12). A product of HO-1 degradation of heme, car-
bon monoxide (CO) has also been shown to be beneficial 
therapeutically in animal models of sepsis (16, 20, 21), and 
inhaled CO gas accelerates the resolution of inflammation 
in zymosan-induced peritonitis (22). Furthermore, ex vivo 
conditioning of cells (23, 24) or even tissues (25) with CO 
has shown protection from cell and organ injury. Thus, in the 
present study, we wanted to determine whether CO precon-
ditioning would improve MSC function and therapeutic effi-
cacy in experimental polymicrobial sepsis, and to determine 
potential mechanisms contributing to this effect.
MATERIAL AND METHODS
Isolation of MSCs and Lung Fibroblasts
Mouse MSCs were harvested from the compact bone of 
BALB/c mice (12 mice/harvest) as described (12), and lung 
fibroblasts were used as control mesenchymal cells. MSCs 
of passage 3–6 were used for experiments. Human MSCs 
were obtained from either Texas A&M Health Science Cen-
ter, Institute for Regenerative Medicine, or Lonza. The cells 
were characterized using a BD fluorescent-activated cell sort-
ing (FACS) Canto II (Becton Dickinson Biosciences, Bedford, 
MA) and analyzed using FlowJo software (Becton Dickinson 
Biosciences). Antibodies used for immunophenotyping of 
cells are listed in Supplemental Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/CCM/C8).
CO Exposure
Cells were exposed to ambient air or CO gas at 250 parts per 
million (ppm) for 4 hours in a chamber that was humidified 
and maintained at 37°C as described (26).
Gene Silencing
For the 5-lipoxygenase (LOX) and 12/15-LOX silencing experi-
ments, lentiviral transfection was used. For detailed infor-
mation, see Supplemental Methods (Supplemental Digital 
Content 2, http://links.lww.com/CCM/C9).
CLP
To induce polymicrobial sepsis, we used an established murine 
model of CLP (two-thirds cecum ligated, two 21-gauge needle 
punctures) as described (12, 16).
Terminal Deoxynucleotidyl Transferase dUTP Nick-
End Labeling Staining
Terminal deoxynucleotidyl transferase dUTP nick-end label-
ing (TUNEL) was performed in the spleen, and the area of 
positive staining was assessed as described (27).
Aspartate Aminotransferase,  
Alanine Aminotransferase, and Creatinine Assays
Aspartate aminotransferase (AST, alanine aminotransferase, 
and creatinine plasma levels were measured by commercially 
available colorimetric assay kits (BioVision, Milpitas, CA).
Assessment of Blood/Peritoneal Colony-Forming 
Units
Serial dilutions of whole blood were performed, and aliquots 
were cultured on Luria-Bertani agar plates as described (12). 
Colony-forming units (CFUs) were counted following over-
night incubation at 37°C. In addition, serial dilutions of peri-
toneal lavages were also performed, and CFUs were counted.
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Neutrophil Isolation
Isolation of mouse and human neutrophils is described in 
the Supplemental Methods (Supplemental Digital Content 2, 
http://links.lww.com/CCM/C9).
Phagocytosis Assay
Neutrophil phagocytosis of green fluorescent protein–labeled 
bacteria, ± MSCs, is described in the Supplemental Methods 
(Supplemental Digital Content 2, http://links.lww.com/CCM/
C9). Bacterial phagocytosis was measured by flow cytometry as 
described (12), and Supplemental Figure 1 (Supplemental Dig-
ital Content 3, http://links.lww.com/CCM/C10; legend, Supple-
mental Digital Content 14, http://links.lww.com/CCM/C21) 
shows our gating strategy and a representative flow cytometry 
pseudocolor density plot for neutrophil phagocytosis.
Efferocytosis Assay
The measurement of macrophages phagocytizing dead neu-
trophils from peritoneal fluid after CLP injury, ± MSCs, is 
described in the Supplemental Methods (Supplemental Digi-
tal Content 2, http://links.lww.com/CCM/C9). Supplemental 
Figure 2 (Supplemental Digital Content 4, http://links.lww.
com/CCM/C11; legend, Supplemental Digital Content 14, 
http://links.lww.com/CCM/C21) demonstrates representa-
tive flow cytometry pseudocolor density plots of efferocytosis 
assays in permeabilized (A) and nonpermeabilized (B) cells.
Lipid Mediator Profiling Using Liquid 
Chromatography-Tandem Mass Spectrometry–Based 
Metabololipidomics
Measurement of lipid mediator profiles was performed as 
described (28). For detailed information, see the Supplemen-
tal Methods (Supplemental Digital Content 2, http://links.lww.
com/CCM/C9).
Quantitative Real-Time Polymerase Chain Reaction, 
Western Blotting, and 3-(4,5-Dimethylthiazol-2-yl)2,5-
Diphenyl-Tetrazolium Bromide Viability Assay
Quantitative real-time polymerase chain reaction (qRT-PCR) 
was performed as described (29). Primer sequences are shown 
in Supplemental Table 2 (Supplemental Digital Content 5, 
http://links.lww.com/CCM/C12). For further details regard-
ing qRT-PCR, Western blotting, or 3-(4,5-dimethylthiazol-
2-yl)2,5-diphenyl-tetrazolium bromide viability assays, see 
the Supplemental Methods (Supplemental Digital Content 2, 
http://links.lww.com/CCM/C9).
Statistical Analysis
Data are expressed as mean ± sem. Comparisons of mortality 
were made by analyzing Kaplan-Meier survival curves, and 
then the log-rank test was performed to assess the differences 
in survival. For comparisons between two groups, we used Stu-
dent unpaired t test. One-way analysis of variance was used 
for analysis of more than two groups. When data were not 
normally distributed, nonparametric analyses were performed 
using Mann-Whitney U or Kruskal-Wallis testing, respectively. 
The numbers of samples per group (n), or the numbers of 
experiments, are specified in the figure legends. Statistical sig-
nificance is accepted at p value less than 0.05.
Study Approval
The care and use of animals for all experiments were approved 
by the Harvard Medical Area Standing Committee on Animals, 
Harvard Medical School. Experiments involving human blood 
donation by consented volunteers, for isolation of neutrophils, 
were approved by the Partners Healthcare Institutional Review 
Board.
RESULTS
Preconditioning of MSCs With CO Sustains the 
Efficacy of the Cells for Survival Benefit in CLP-
Induced Sepsis
MSCs phenotypically adhered to plastic and expressed mark-
ers of mesenchymal origin (CD105, CD90.2, CD73, CD140b, 
CD29, CD44) and Sca1, but not markers of hematopoietic ori-
gin (such as CD45, CD11b, and bone marrow lineage markers) 
or major histocompatibility complex II (Supplemental Fig. 3A, 
Supplemental Digital Content 6, http://links.lww.com/CCM/
C13; legend, Supplemental Digital Content 14, http://links.lww.
com/CCM/C21). In addition, the cells showed multipotency in 
vitro by differentiating into osteoblasts, adipocytes, and chon-
drocytes (Supplemental Fig. 3B, Supplemental Digital Content 
6, http://links.lww.com/CCM/C13; legend, Supplemental Digi-
tal Content 14, http://links.lww.com/CCM/C21). To understand 
the effect of CO preconditioning on MSCs, we administered 
the cells in vivo to mice after the onset of CLP-induced sep-
sis. MSCs or control fibroblasts—exposed to ambient air or 
CO at 250 ppm × 4 hours—were initially IV administered 2 
hours (5.0 × 105 cells), 24 hours (2.5 × 105 cells), and 48 hours 
(2.5 × 105 cells) after CLP surgery. The administration of MSCs 
increased survival (65%) compared with fibroblasts (22%) after 
the onset of sepsis (Fig. 1A). Preconditioning of MSCs with CO 
tended to further increase survival (88%) compared with non-
conditioned MSCs, although this was not a statistically signifi-
cant increase. However, mice receiving MSCs preconditioned 
with CO had a marked increase in survival compared with mice 
receiving fibroblasts or fibroblasts preconditioned with CO 
(37%). To determine whether the effects of CO were dependent 
on the expression of HO-1, we preconditioned either wild-type 
or HO-1–deficient MSCs and administered the cells 2, 24, and 
48 hours after CLP surgery. Supplemental Figure 4 (Supple-
mental Digital Content 7, http://links.lww.com/CCM/C14; leg-
end, Supplemental Digital Content 14, http://links.lww.com/
CCM/C21) demonstrates that the mice had a nearly identical 
survival after the onset of sepsis, when receiving either wild-
type or HO-1–deficient MSCs preconditioned with CO. Finally, 
we administered MSCs later after the onset of sepsis (6 hr), and 
in only one dose (5.0 × 105), to further investigate the effects of 
CO preconditioning on MSCs (Fig. 1B). In this setting, mice 
receiving MSCs preconditioned with CO had a significantly 
improved survival (76%) compared with mice treated with 
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MSCs that were not exposed to CO (38%). These data demon-
strate that CO preconditioning of MSCs sustained their ben-
eficial effects when administered later after the onset of sepsis, 
and in a single dose of fewer total cells. In contrast, the efficacy 
of MSCs not preconditioned with CO was lost when given later 
and in a single dose (Fig. 1B). Exposure of MSCs to CO did not 
alter baseline viability of the cells, and in the presence of oxida-
tive stress (H
2
O
2
), CO preconditioning increased MSC survival 
(Supplemental Fig. 5, Supplemental Digital Content 8, http://
links.lww.com/CCM/C15; legend, Supplemental Digital Con-
tent 14, http://links.lww.com/CCM/C21).
Preconditioning of MSCs With CO Further Decreases 
Organ Injury Associated With Polymicrobial Sepsis
One of the most sensitive organs to the injurious effects of 
sepsis is the spleen (30). Postmortem spleens from patients 
dying of sepsis have shown that apoptosis of lymphocytes in 
the white pulp is a prominent feature of injury (31, 32). In the 
present study, representative images of splenic tissue 24 hours 
after CLP surgery showed a marked increase in TUNEL stain-
ing in mice receiving fibroblast control cells compared with 
sham mice (Fig. 2A). The administration of MSCs 6 hours 
after the onset of sepsis resulted in reduced cell death within 
the spleens of mice receiving MSCs preconditioned with CO 
(Fig. 2A). The reduction in liver and kidney injury was also evi-
dent in mice receiving MSCs preconditioned with CO. Plasma 
levels of AST, alanine transaminase, and plasma creatinine 
were increased in septic mice receiving fibroblasts compared 
with sham-operated mice (Fig. 2, B and C respectively). How-
ever, plasma levels of liver enzymes were decreased in mice 
receiving MSCs compared with control fibroblasts, and further 
decreased in mice treated with MSCs preconditioned with CO 
(Fig. 2B). In regard to creatinine, only administration of MSCs 
preconditioned with CO was able to reduce the level during 
sepsis (Fig. 2C).
Preconditioning of MSCs With CO Improves Bacterial 
Clearance and Increases Neutrophil Phagocytosis
Bacterial clearance was assessed from the peritoneum and 
blood 24 hours after the onset of polymicrobial sepsis. Mice 
undergoing CLP-induced sepsis, and receiving control fibro-
blasts, revealed a marked increase in CFUs for bacteria in the 
peritoneum (Fig 3A, left) and blood (Fig. 3A, right) compared 
with sham mice. Mice receiving MSCs, compared with fibro-
blasts, 6 hours after CLP surgery showed a trend for decreased 
bacterial CFUs. However, bacterial CFUs in both the perito-
neum and blood (Fig. 3, A and B) were significantly decreased 
in the mice receiving MSCs preconditioned with CO.
We previously demonstrated that the interaction of MSCs 
with neutrophils is critical for bacterial clearance after poly-
microbial sepsis (12). In the present study, MSCs promoted 
an increase in phagocytosis of Gram-negative Escherichia coli 
and Gram-positive Enterococcus faecalis by neutrophils, and 
exposure of MSCs to CO led to a further increase in neutrophil 
phagocytosis (Fig. 3B). Similarly, conditioned medium from 
MSCs was able to increase neutrophil phagocytosis, which 
was further increased by the conditioned medium from MSCs 
exposed to CO (Fig. 3C).
Preconditioning of MSCs With CO Promotes the 
Resolution of Inflammation During Polymicrobial 
Sepsis
Next we investigated whether MSCs would increase the clearance 
of apoptotic neutrophils by macrophages in the peritoneum (effe-
rocytosis), which is an important process during the resolution of 
inflammation (33). Treatment with MSCs 6 hours after the onset 
of CLP-induced sepsis was able to increase peritoneal efferocytosis 
compared with fibroblasts; however, MSCs preconditioned with 
CO had a more marked increase in efferocytosis (Fig 4A).
Coinciding with the process of efferocytosis, SPMs are 
produced to help orchestrate the resolution of inflammation 
(6, 33). Because culture conditions alone, in contrast to the in 
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Figure 1. Administration of mesenchymal stromal cells (MSCs) 
preconditioned with carbon monoxide (CO) improves efficacy of the 
cells and survival in cecal ligation and puncture (CLP)-induced sepsis. 
A, BALB/c mice were randomly separated into four groups: fibroblasts 
(Fibro), dashed gray line, n = 9; Fibro+CO, solid gray line, n = 8; MSCs, 
dashed black line, n = 17; and MSCs+CO, solid black line, n = 17. All 
mice were subjected to CLP, and 2 hr later the mice were treated with 
5 × 105 cells by tail vein injection. Treatments were repeated at 24 and 
48 hr after surgery with 2.5 × 105 cells. Survival of mice was monitored 
for 7 d, and data are presented as a Kaplan-Meier survival curve, and 
analyzed by log-rank test. * MSCs versus Fibro, p = 0.034; * MSCs+CO 
versus Fibro, p = 0.0002; and † MSCs+CO versus Fibro+CO, p = 0.003. 
B, BALB/c mice were randomly separated into two groups: MSCs, 
dashed black line, n = 21; and MSCs+CO, solid black line, n = 21. All 
mice were subjected to CLP, and after 6 hr the mice were treated with 
5 × 105 cells by tail vein injection. Survival of mice and data analysis as 
described in (A). *MSCs+CO versus MSCs, p = 0.016.
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vivo setting, do not provide the necessary substrates for pro-
duction of SPMs, we incubated CO preconditioned MSCs with 
either DHA or AA to help elucidate the mediators contributing 
to the beneficial MSC response. Figure. 4B demonstrates that 
administration of CO preconditioned MSCs to mice 6 hours 
after the onset of CLP-induced sepsis led to a significantly 
improved survival when the cells were exposed to DHA (92% 
survival), compared with cells exposed to AA (58% survival). 
The cells exposed to DHA predominantly expressed SPMs, 
whereas the cells exposed to AA expressed eicosanoids (Fig. 4C).
To determine SPMs produced by MSCs preconditioned with 
CO, we performed liquid chromatography-tandem mass spec-
trometry. Supplemental Figure 6 (Supplemental Digital Content 
9, http://links.lww.com/CCM/C16; legend, Supplemental Digital 
Content 14, http://links.lww.com/CCM/C21) shows representa-
tive multiple reaction monitoring traces (A) for the measured lipid 
mediators and accompanying tandem mass spectrometry spectra 
(B) used for identification. As 
seen in Figure. 4D, SPMs were 
greater in DHA exposed cells, 
compared with AA exposed cells, 
particularly D-series resolvins 
(Rv). An entire profile of SPMs 
is shown in Supplemental 
Table 3 (Supplemental Digital 
Content 10, http://links.lww.
com/CCM/C17), and a com-
plete list of abbreviations is pro-
vided in Supplemental Table 4 
(Supplemental Digital Content 
11, http://links.lww.com/CCM/
C18). We next used representa-
tive D-series Rv (RvD1, RvD2, 
and aspirin triggered [AT]-
RvD3) to assess their role in 
the interaction of MSCs with 
neutrophils to promote bacte-
rial phagocytosis. To confirm 
this response was applicable in 
human cells, we used human 
MSCs and neutrophils. MSCs 
increased the phagocytosis of E. 
coli by neutrophils, and MSCs 
preconditioned with CO pro-
duced an enhanced phagocytic 
response (Fig. 4E). Incubation of 
neutrophils with RvD1, RvD2, or 
AT-RvD3 alone showed evidence 
of neutrophil phagocytosis of E. 
coli. However, when MSCs were 
exposed to either RvD1 or RvD2, 
and then incubated with neutro-
phils, phagocytosis was robustly 
increased compared with neu-
trophils exposed to RvDs alone 
or MSCs alone, to a level analo-
gous to neutrophils incubated with MSCs preconditioned with CO 
(Fig. 4E). Exposure of MSCs to AT-RvD3 did not promote neutro-
phil phagocytosis to a level significantly greater than neutrophils 
exposed to MSCs alone.
5-LOX and 12/15-LOX Are Critical Enzymes for CO-
Induced MSC Function and Benefit in Sepsis
LOXs are the enzymes responsible for the biosynthesis of SPMs, 
with both 5-LOX and 12/15-LOX pathways contributing to the 
production of Rv from DHA (34, 35). To further assess the role 
of SPMs in promoting neutrophil phagocytosis by MSCs, we 
pretreated MSCs with the LOX inhibitor baicalein, and then 
incubated ambient air- or CO-exposed MSCs with neutrophils. 
Baicalein blunted the ability of ambient air-exposed MSCs to 
promote neutrophil phagocytosis, and the LOX inhibitor abol-
ished the enhanced phagocytic response of neutrophils exposed 
to CO preconditioned MSCs (Fig. 5A). This lack of a CO response 
A
LT
 U
/L
A
S
T 
U
/L
CLP
MSCs
CO
Fibro
–
–
–
–
+
+
–
–
+
–
+
–
+
–
+
+
CLP
MSCs
CO
Fibro
–
–
–
–
+
+
–
–
+
–
+
–
+
–
+
+
C
re
at
in
in
e 
nm
ol
/µ
l
CLP
MSCs
CO
Fibro
–
–
–
–
+
+
–
–
+
–
+
–
+
–
+
+
*
† ‡
*
* † ‡
* † *
† ‡
*
* †
B C
Sham
CLP+MSCs
CLP+Fibro
CLP+MSCs/CO
CLP
MSCs
CO
Fibro
– + + +
– + – –
– – + +
– – – +
*
†
*
A
re
a 
(%
) T
U
N
E
L 
st
ai
ni
ng
A
6
5
4
3
2
1
0
300
250
200
150
100
50
0
70
60
50
40
30
20
10
0
0.4
0.3
0.2
0.1
0.0
Figure 2. Administration of mesenchymal stromal cells (MSCs) preconditioned with carbon monoxide (CO) 
decreases tissue injury in cecal ligation and puncture (CLP)-induced sepsis. Mice were subjected to sham or CLP 
surgery (CLP+fibroblasts [Fibro], CLP+MSCs, CLP+MSCs/CO). A total of 5 × 105 cells were administered by tail 
vein injection 6 hr after CLP. At 24 hr, mice were anesthetized, and blood and spleens were harvested. A, Spleen 
injury was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (brown 
staining, right), and quantitated (left). The bar in the sham represents a length of 50 μm. Data are presented as box 
plots, which show median values and interquartile ranges. Analysis was done by Kruskal-Wallis testing (also used in 
B and C). Sham, white bar, n = 3; CLP+Fibro, light gray bar, n = 7; CLP+MSCs, dark gray bar, n = 8; CLP+MSCs/
CO, striped bar, n = 8. p = 0.0001, with significant comparisons * versus sham and † versus CLP+Fibro. B, Plasma 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) data are shown as box plots. Sham,  
n = 3; CLP+Fibro, light gray bar, n = 6; CLP+MSCs, dark gray bar, n = 8; CLP+MSCs/CO, striped bar, n = 9.  
p = 0.002 and p = 0.0008, respectively, with significant comparisons * versus sham, † versus CLP+Fibro, and ‡ 
versus CLP+MSCs. C, Plasma creatinine levels are shown as box plots. Sham, n = 3; CLP+Fibro, light gray bar,  
n = 6; CLP+MSCs, dark gray bar, n = 6; CLP+MSCs/CO, striped bar, n = 5. p = 0.018, and significant 
comparisons of specific groups * versus sham, † versus CLP+Fibro, and ‡ versus CLP+MSCs.
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was evident in both human (Fig. 
5A, left) and mouse (Fig. 5A, 
right) MSCs. To delineate the 
response of LOX enzymes to CO, 
we exposed either MSCs or con-
trol fibroblasts to ambient air or 
CO (250 ppm) and then assessed 
the level of 5-LOX or 12/15-
LOX messenger RNA (mRNA) 
by qRT-PCR. The basal levels 
of both 5-LOX and 12/15-LOX 
were low in fibroblasts and not 
inducible by CO. Interestingly, 
the basal level of 5-LOX was 
significantly greater in MSCs 
compared with fibroblasts, and 
CO caused a further increase in 
5-LOX expression (Fig. 5B, top). 
In contrast, the basal level of 
12/15-LOX was not significantly 
different between fibroblasts and 
MSCs; however, the exposure of 
CO caused a marked increase in 
the level of 12/15-LOX (Fig. 5B, 
bottom). Thus, in MSCs, both the 
5-LOX and 12/15-LOX enzymes 
are induced by exposure to CO.
Finally, to determine 
whether the 5-LOX and 12/15-
LOX enzymes are critical for 
MSC function, we silenced 
these enzymes in mouse MSCs 
(silencing of 5-LOX and 12/15 
LOX [shLOX] [as described in 
the narrative]) or introduced 
a scrambled shRNA sequence 
(shSCR). Supplemental Figure 
7 (Supplemental Digital Content 
12, http://links.lww.com/CCM/
C19; legend, Supplemental 
Digital Content 14, http://links.
lww.com/CCM/C21) demon-
strates a reduction in 5-LOX 
and 12/15-LOX mRNA, pro-
tein, and a reduction in RvD1 
and RvD2 production in shLOX 
cells. Although shSCR MSCs 
produced an increase in neu-
trophil phagocytosis, there was 
no significant increase in neu-
trophil phagocytosis by shLOX 
MSCs (targeting both 5-LOX 
and 12/15-LOX enzymes). Even 
more impressive, shLOX MSCs 
preconditioned with CO had a 
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Figure 3. Administration of mesenchymal stromal cells (MSCs) preconditioned with carbon monoxide 
(CO) improves bacterial clearance in cecal ligation and puncture (CLP)-induced sepsis and increases 
bacterial phagocytosis by neutrophils. A, Mice were subjected to sham or CLP surgery (CLP+fibroblasts 
[Fibro], CLP+MSCs, CLP+MSCs/CO). A total of 5 × 105 cells were administered by tail vein injection 6 hr 
after CLP. At 24 hr, peritoneal fluid (left) and blood samples (right) were collected and analyzed. Data are 
presented as box plots, which show median values and interquartile ranges. Analysis was done by Kruskal-
Wallis testing (also used in B and C). Left, sham, n = 11; CLP+Fibro, white box, n = 6; CLP+MSCs, 
light gray box, n = 9; CLP+MSCs/CO, dark gray box, n = 12. Right, sham, n = 7; CLP+Fibro, white 
box, n = 6; CLP+MSCs, light gray box, n = 10; CLP+MSCs/CO, dark gray box, n = 12. p < 0.0001 
left and p = 0.001 right, with significant comparisons * versus sham, † versus CLP+Fibro, and ‡ versus 
CLP+MSCs. B, Isolated neutrophils were incubated with green fluorescent protein (GFP)-labeled E. coli 
or E. faecalis in the presence of MSCs (light gray bars), MSCs+CO (dark gray bars) or in the absence 
of MSCs (white bars). Data are presented as box plots, n = 5–7 per groups from three independent 
experiments. p < 0.0008 for E. coli and p = 0.0022 for E. faecalis, with significant comparisons * 
versus no MSCs, and † versus MSCs. C, Isolated neutrophils were incubated with GFP-labeled E. coli 
or E. faecalis with addition of conditioned medium (CM) from MSCs (light gray bars), MSCs+CO (dark 
gray bars), or basal medium (white bars). Data are presented as box plots, n = 4–5 per group from 
three independent experiments. p < 0.0064 for E. coli and p < 0.0047 for E. faecalis, with significant 
comparisons * versus basal medium, and † versus CM of MSCs.
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markedly blunted effect on neu-
trophil phagocytosis compared 
with SCR shRNA MSCs precon-
ditioned with CO (Fig. 5C). This 
blunted neutrophil phagocytosis 
response was rescued by admin-
istration of exogenous RvD1 or 
RvD2. Silencing of 5-LOX or 
12/15-LOX enzymes individually 
did not significantly blunt the 
MSC response (Supplemental 
Fig. 8, Supplemental Digital 
Content 13, http://links.lww.com/
CCM/C20; legend, Supplemental 
Digital Content 14, http://links.
lww.com/CCM/C21), suggesting 
that both enzymes contribute to 
the ability of MSCs to promote 
neutrophil phagocytosis, par-
ticularly after preconditioning 
with CO. This effect of silenc-
ing both 5-LOX and 12/15-LOX 
in MSCs was also translated to 
their in vivo response. shLOX 
MSCs preconditioned with CO 
and administered to septic mice 6 
hours after CLP had a decreased 
survival (43%) compared with 
shSCR MSCs exposed to CO 
(79%) (Fig. 5D). These data sug-
gest that silencing of 5-LOX and 
12/15-LOX enzymes led to a loss 
of improved efficacy afforded to 
MSCs by preconditioning with 
CO. Interestingly, the survival rate 
of mice receiving shLOX MSCs 
preconditioned with CO (43%) 
is comparable with the survival 
rate of mice receiving MSCs not 
preconditioned with CO (38%), 
when injected 6 hours after CLP.
DISCUSSION
Gas molecules have been pro-
posed as therapeutic agents for 
a variety of disease processes, 
including lung and even systemic 
illnesses (36, 37). One such gas is 
CO, which has been shown to 
be beneficial therapeutically in 
animal models of sepsis (16, 20, 
21). Although preclinical studies 
and clinical trials are ongoing to 
more fully evaluate the safety and 
effectiveness of administering 
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Figure 4. Carbon monoxide (CO) preconditioning induces production of specialized proresolving lipid mediators 
(SPMs) in mesenchymal stromal cells (MSCs), which mimic the CO effect by enhancing neutrophil phagocytosis 
of bacteria. A, Mice were subjected to sham or cecal ligation and puncture (CLP) surgery (CLP+fibroblasts [Fibro], 
CLP+MSCs, CLP+MSCs/CO). A total of 5 × 105 cells were administered by tail vein injection 6 hr after CLP. At 24 hr, 
peritoneal fluid was collected and efferocytosis assays were performed. Data are presented as box plots, which show 
median values and interquartile ranges. Sham, n = 3; CLP+Fibro, light gray bar, n = 6; CLP+MSCs, dark gray bar,  
n = 6; CLP+MSCs/CO, striped bar, n = 7. Analysis was done by Kruskal-Wallis testing (p = 0.0004), with significant 
comparisons * versus sham, † versus CLP+Fibro, and ‡ versus CLP+MSCs. B, Mice were subjected to CLP, and 6 hr 
later, the mice received 5 × 105 MSCs treated with CO in the presence of docosahexaenoic acid (DHA) (10 μM), 
solid black line, n = 12 or MSCs-treated with CO in the presence of arachidonic acid (AA) (10 μM), dashed black 
line, n = 12. Survival of mice was monitored for 7 d and data are presented as a Kaplan-Meier survival curve, and 
analyzed by log-rank test. *versus MSCs+CO (AA), p = 0.040. C, Human MSCs were exposed to CO in the presence 
of DHA or AA, followed by lipid mediator profiling. Total SPMs are shown left, and total eicosanoids right. Data are 
presented as box plots, n = 4 samples per group from two independent experiments. Analysis was done by Mann-
Whitney U testing. * versus MSCs+CO in the presence of AA (p = 0.03 for SPMs and p = 0.03 for eicosanoids). D, 
Representative pie charts of SPM levels in MSCs conditioned with CO, in the presence of DHA or AA. E, Human 
neutrophils were incubated with green fluorescent protein-labeled E. coli alone (white bars, n = 16), in the presence 
of MSCs (gray bar, n = 16), or in the presence of CO-conditioned MSCs (black bar, n = 16) or MSCs conditioned 
with resolvin D1 (RvD1, 10 nM), Rv D2 (10 nM), or aspirin-triggered Rv D3 (AT-RvD3, 10 nM) (black bars, n = 8). Data 
are presented as fold increase in mean fluorescence intensity, mean ± sem, from three independent experiments. 
Analysis was done by one-way analysis of variance (p < 0.0001), with significant comparisons * versus no MSCs, † 
versus MSCs, and ‡ versus its RvD control. HETE = hydroxyeicosatetraenoic acid, Lx = lipoxin, PD1 = Protectin D1.
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CO in vivo for the treatment 
of human diseases (38), the 
goal of the present study was to 
promote the beneficial effects 
of CO on MSCs ex vivo and 
then administer the cells after 
the onset of polymicrobial sep-
sis in mice.
Studies have investigated 
various molecular and genetic 
modifications of MSCs to 
improve cell viability and func-
tion, with particular inter-
est in cardiovascular diseases 
(9, 39). MSCs are known to 
repair injured tissues with-
out evidence for significant 
engraftment or differentiation, 
through paracrine actions (40). 
Conditioning of MSCs with 
cytokines, growth factors, and 
toll-like receptor ligands has 
also been performed in an effort 
to increase their therapeutic 
potential, with an interest in 
modulation of inflammatory 
responses (41–43). To our 
knowledge, the present study is 
the first use of preconditioning 
MSCs with CO ex vivo to treat 
experimental sepsis.
HO-1 and its product CO 
have known cytoprotective 
properties (44), and it has been 
shown in MSCs that overex-
pression of HO-1 or incubation 
with compounds that release 
CO can increase cell viability 
during myocardial ischemia and 
neural differentiation, respec-
tively (45, 46). We also show 
that in the setting of increased 
oxidative stress, as occurs during 
sepsis, preconditioning of MSCs 
with CO is able to increase cell 
viability (Supplemental Fig. 5, 
Supplemental Digital Content 
8, http://links.lww.com/CCM/
C15; legend, Supplemental 
Digital Content 14, http://
links.lww.com/CCM/C21). 
Furthermore, we now dem-
onstrate that MSCs precondi-
tioned with CO have improved 
efficacy, allowing therapy to 
be administered at later time 
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Figure 5. Lipoxygenase pathways contribute to the carbon monoxide (CO)-mediated effects of mesenchymal 
stromal cells (MSCs) on neutrophil phagocytosis, and silencing of 5-lipoxygenase (LOX) and 12/15-LOX 
results in a loss of improved MSC efficacy by CO conditioning. A, MSCs were pretreated with baicalein  
(10 μM) or vehicle, and then cocultured with human (left) or mouse (right) neutrophils in the presence or 
absence of green fluorescent protein (GFP)-labeled E. coli. Data are presented as box plots, which show 
median values and interquartile ranges. Analysis was done by Kruskal-Wallis testing (also used in B). n = 4–5 
per group from three independent experiments. p = 0.0016 and p = 0.0062, human and mouse, respectively, 
and significant comparisons of specific groups * versus no MSCs, † versus MSCs, and ‡ between designated 
groups. B, Fibroblasts (Fibro) and MSCs were incubated with CO or ambient air for 4 hr, and then RNA was 
extracted and quantitative real-time polymerase chain reaction performed for 5-LOX (upper) and 12/15-LOX 
(lower). Data are presented as box plots, n = 4–6 per group from three independent experiments.  
p = 0.0008 for 5-LOX and 12/15-LOX, with significant comparisons * versus Fibro, † versus Fibro+CO, and  
‡ versus MSCs. C, MSCs were silenced with scrambled (SCR), or both 5-LOX and 12/15-LOX = small hairpin 
RNAs (shRNAs) (method used to silence 5-LOX and 12/15 LOX (shLOX [defined in the narrative of the 
article]). The MSCs were exposed to CO or ambient air, and then cocultured with neutrophils in the presence 
of GFP-labeled E. coli. shLOX MSCs exposed to CO were also exposed to resolvin D1 (RvD1, 10 nM) or Rv 
D2 (10 nM). Data are presented as fold increase in mean fluorescence intensity, mean ± sem, n = 6–12 per 
group from three independent experiments. Analysis was done by one-way analysis of variance (p < 0.0001) 
with significant comparisons * versus no MSCs, † versus MSCs (SCR shRNA sequence [shSCR]), and ‡ 
between designated groups. D, BALB/c mice were randomly separated into two groups, shSCR MSCs+CO 
(solid black line, n = 14) or shLOX MSCs+CO (dashed black line, n = 14). Six hours after cecal ligation and 
puncture (CLP), the mice were treated with 5 × 105 cells by tail vein injection. Animal survival was monitored 
for 7 d, and data are presented as a Kaplan-Meier survival curve, and analyzed by log-rank test. * versus 
shSCR MSCs+CO, p = 0.049. GAPDH = glyceraldehyde-3-phosphate dehydrogenase, mRNA = messenger 
RNA, NS = not significant.
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points after the onset of sepsis, and with fewer total cells, whereas 
nonconditioned MSCs lose their therapeutic efficacy. Thus, CO 
preconditioned MSCs lead to increased survival (Fig. 1), less 
organ injury (Fig. 2), and improved bacterial clearance (Fig. 3) 
during experimental sepsis.
Once the invading bacteria are cleared, the resolution of 
inflammation is necessary to regain homeostasis and prevent 
organ injury during sepsis. SPMs are produced to coordi-
nate the resolution response (6, 33, 35). In the presence of 
DHA substrate, MSCs exposed to CO predominantly pro-
duced SPMs and improved survival when administered after 
the onset of sepsis, whereas MSCs exposed to AA substrate 
resulted in eicosanoid production and reduced survival 
(Fig. 4). When assessing the differences in SPMs, the pro-
duction of Rv family members was greater in cells exposed 
to DHA versus AA (Fig. 4). Interestingly, it was previously 
shown by Spite et al (47) that RvD2 improved survival in 
CLP-induced polymicrobial sepsis by regulating the inflam-
matory response, phagocytosis, and bacterial clearance. 
Taken together, these data suggest that production of SPMs 
(particularly D-series Rv) may contribute to the improved 
therapeutic response of MSCs exposed to CO ex vivo.
To confirm the importance of SPM production in MSCs 
preconditioned with CO, we exposed MSCs to a LOX inhibitor 
(baicalein) or silenced both 5-LOX and 12/15-LOX enzymes in 
MSCs. Either maneuver resulted in a loss of enhanced neutro-
phil phagocytosis induced by CO preconditioned MSCs (Fig. 5, 
A and C). In addition, silencing of both 5-LOX and 12/15-LOX 
resulted in a loss of survival benefit for MSCs preconditioned 
with CO, and a loss of MSCs efficacy when administered 6 
hours after CLP-induced sepsis (Fig. 5D).
It has been suggested that exposure to CO promotes a 
beneficial response, in part, through a positive feedback loop 
increasing the production of its parent enzyme HO-1 (22, 48). 
In addition, the proresolving lipid mediator lipoxin A
4
 (LXA
4
) 
is known to increase HO-1 expression (49). However, we found 
that endogenous HO-1 was not required for the beneficial 
CO preconditioning response of MSCs during sepsis because 
HO-1–deficient cells were as effective as wild-type MSCs in 
protecting mice from CLP-induced mortality (Supplemental 
Fig. 4, Supplemental Digital Content 7, http://links.lww.com/
CCM/C14; legend, Supplemental Digital Content 14, http://
links.lww.com/CCM/C21).
Recently it was shown that human MSCs cocultured with alve-
olar epithelial type II cells have increased production of LXA
4
 in 
the presence of proinflammatory cytokines (50). MSCs were also 
able to promote the resolution of acute lung injury induced by E. 
coli lipopolysaccharide, and this occurred in part by production 
of LXA
4
 (50). Conversely, in our study, LxA
4
 was expressed by CO 
preconditioned MSCs only in the presence of AA (Fig. 4D; and 
Supplemental Table 3, Supplemental Digital Content 10, http://
links.lww.com/CCM/C17), which resulted in the production of 
predominantly eicosanoids (Fig. 4C) and led to decreased sur-
vival in CLP-induced sepsis (Fig. 4B). The imbalance of increased 
production of AA-derived proinflammatory eicosanoids, and less 
production of SPMs (i.e., LxA4), likely contributed to a worse 
outcome. Taken together, these data suggest that LXA
4
 is not 
playing as significant of a role in the MSC response to CO expo-
sure, and its effect on outcome during polymicrobial sepsis.
Although the present study advanced our understanding of 
the therapeutic effects of MSCs in sepsis, we are presently lim-
ited to using a mouse model of disease. Furthermore, MSCs were 
not used in conjunction with antibiotics and hemodynamic 
resuscitation, standards of care for human patients, and they 
will need to be tested in the future. We believe that conditioning 
of MSCs with CO has the potential for future application; how-
ever, in this early stage of investigation, CO-conditioned MSCs 
are not immediately translatable to clinical application.
CONCLUSION
In the present study, we demonstrate that preconditioning of 
MSCs with CO gas improved MSC function and therapeutic effi-
cacy during sepsis. Data including inhibition or silencing of LOX 
enzymes (5-LOX and 12/15-LOX) support the concept that the 
increased beneficial response of MSCs exposed to CO occurred 
in part through the production of SPMs, which contributed to 
the interaction of MSCs with neutrophils to promote bacterial 
phagocytosis, resolution of inflammation, and increased sur-
vival. We propose that MSCs preconditioned with CO may have 
future implications for the treatment of sepsis, allowing a ben-
eficial response even with a delayed initiation of therapy.
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